Wockhardt sets up its first manufacturing and R&D unit in Middle East
Shalini | Myequity news | Date : 30-07-2018 11:30:00 IST
Wockhardt Group, a Global Pharmaceutical and Biotech major, sets up its firstfacility in Middle East for manufacturing of NCEs (New Chemical Entities) catering to the globalmarkets through its Dubai arm of its subsidiary Wockhardt Bio AG. The 'state-of-the-art' manufacturing facility meant for the production and packaging of sterile dry powder injection. On approval of the new drug by US FDA, this manufacturing facility will be commissioned for commercial production.
"Wockhardt is poised for a quantum leap into the future. It is a future ofdynamic changes, exciting possibilities and endless potential to further its goal of 'Life Wins'and Wockhardt is committed to shaping this future. With Wockhardt's commitment to R&D, wehave 5 breakthrough New Chemical Entities (NCEs) that have been accorded QualifiedInfectious Disease Product (QIDP) status by US FDA. With the new facility in Middle East, weaim to focus on our commitment in developing NCEs to fight the health issues faced." Dr. Habil Khorakiwala, Founder Chairman of Wockhardt said.
Antimicrobial resistance (AMR) - the ability of infections to resist antibiotics to work against it isincreasingly recognized as growing global health problem. Infections caused by antimicrobialresistant strains of bacteria-also called "superbugs" are unlikely to respond to standardtreatments resulting in prolonged illness and a greater risk to health, and severely impactingclinical outcomes, leading to further higher healthcare costs due to consumption of healthcareresources.
Wockhardt currently has 5 novel antibiotic drugs in advanced stages of global clinicaldevelopment which will be effective against these "superbugs" threats identified by the Centerof Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDAhas granted Qualified Infectious Disease Program (QIDP) status to the 5 novel antibiotic drugs.
"Wockhardt has dedicated significant resources for the discovery and development of novelantibiotics. These novel drugs in advanced stages of global development are a culmination of20 years of dedicated and focused research in the antibiotics therapy segment with an aim toimprove the quality of life", said Dr. Murtaza Khorakiwala, Managing Director of Wockhardt.
"Wockhardt conducted extensive studies for identifying a region in the Middle East to establisha strong manufacturing presence for its advanced patented drugs. JAFZA was found to beappropriate for the factory premises for manufacturing patented proprietary drugs for globalmarkets", added Dr. Habil Khorakiwala.
Wockhardt Bio AG manufacturing facility is designed to meet standards of various internationalregulatory agencies and the standards as set by the Local Ministry of Health. The facility meetsthe needs of Aseptic Dry Powder Injectable manufacturing and filling with a high qualityoperation. This facility is dedicated to launch its novel New Chemical Entities in the Antibioticssegment to the world from UAE.
The facility is spread over 10,000 sq. meters of space, self-sufficient for handling Warehousing,Manufacturing Operations, Product Testing and Product Stability. The facility is equipped withbest-in-class and fully automated manufacturing equipments and clean utility systems. Thedesign takes into account the requirements for Product & Personnel Safety and Product Qualitywith complete close transfers and high levels of sterility assurances.
Antimicrobial resistance (AMR) - the ability of infections to resist antibiotics to work against it is increasingly recognized as growing global health problem. Infections caused by antimicrobial resistant strains of bacteria-also called "superbugs" are unlikely to respond to standard treatments resulting in prolonged illness and a greater risk to health, and severely impacting clinical outcomes, leading to further higher healthcare costs due to consumption of healthcare resources.Wockhardt currently has 5 novel antibiotic drugs in advanced stages of global clinical development which will be effective against these "superbugs" threats identified by the Center of Disease Control, USA. Considering the strategic importance of these antibiotics, the US FDA has granted Qualified Infectious Disease Program (QIDP) status to the 5 novel antibiotic drugs.
Wockhardt is a Global Pharmaceutical and Biotech company employing over 9,000 people and 27nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many othercountries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility inIreland. Wockhardt has a significant presence in USA, Europe and India, with 62% of its globalrevenues coming from international businesses. Wockhardt is home to 600 plus scientists, of whom, 70plus are doctorates.
Wockhardt is the only company in the world where USFDA has given QIDP Status(Qualified Infectious Diseases Programme) for 5 of our Anti-bacterial discovery programmes - 2 of themare Gram Negative and 3 Gram Positive effective against untreatable "Superbugs". Wockhardt's entireAnti-infective portfolio particularly addresses the specific bacterial organism where resistances are highand breakthrough antibiotics are needed.
Wockhardt Limited closed 3.12% up at Rs 595.90